Meridia


sibutramine

A central, appetite-suppressing agent that blocks reuptake of serotonin, norepinephrine and, to a lesser extent, dopamine; it provides a sensation of fullness from lesser amounts of food, and increases metabolism. Sibutramine was approved for use as a dietary adjunct in the mid-1990s and was heavily marketed until 2010, when it was withdrawn from the market due to the increased risk of cardiovascular events and strokes associated with its use. Sibutramine is a Schedule-IV Controlled Substance.
 
Indications
Obese patients with an initial BMI of ≥ 30 kg/m2 or ≥ 27 kg/m2 in addition to other factors (e.g., hypertension, diabetes, dyslipidemia).
Adverse effects
Headache, dry mouth, anorexia, constipation.
Contraindications
Concurrent MAOIs, other central appetite suppressants, anorexia nervosa.

Meridia®

Sibutramine Obesity An anti-obesity agent used to facilitate and maintain weight loss, coupled to a low-calorie diet Contraindications Hx of stroke, CAD, CHF, uncontrolled HTN. See Obesity. Cf Xenical.